← All trials
NCT03184194
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 15, 2017
- Primary completion
- Jul 15, 2019
- Completion date
- Jul 15, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of AmsterdamLead sponsor
- Utrecht UniversityCollaborator
- University of GroningenCollaborator
- Maastricht UniversityCollaborator
- Albert Schweitzer ZiekenhuisCollaborator
- Radboud UniversityCollaborator
- Netherlands Cancer InstituteCollaborator
- Free University of AmsterdamOverall official - principal investigator
- Meander Medical CenterCollaborator
- Free University of AmsterdamReponsible party - principal investigator
- Isala Clinics, Zwolle, The NetherlandsCollaborator
- Rijnstate HospitalCollaborator
- Erasmus University RotterdamCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.